Title
Category
Credits
Event date
Cost
  • Alzheimer Disease
  • Antipsychotics
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • Parkinson Disease
  • Psychotic Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Antipsychotics can be used in the short-term to manage dementia-related psychosis, but serious adverse effects can outweigh benefits. Novel antipsychotics or other agents may offer superior efficacy and safety. Explore the evidence in this CME activity.
  • Patient/Physician Communication
  • Mood Disorders
  • Child and Adolescent Psychiatry
  • Depression
  • Bipolar Disorder
  • Antipsychotics
  • Antidepressants
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Findling and Goldberg offer expertise on the diagnosis and treatment of bipolar disorder in patients of all ages.
  • Bipolar Disorder
  • Antipsychotics
  • Women’s Mental Health
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What do data from a pregnancy registry demonstrate about the risk of major malformations among infants exposed to second-generation antipsychotics during the first trimester?
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients may be more willing to accept some adverse effects than others. Dr Kane offers advice on addressing side effects that prevent patients from maintaining their medication adherence.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotherapy
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Can a patient-centered approach to treatment be adopted for patients with schizophrenia? Can these patients take part in shared decision-making? Follow along as Dr Harvey shares his expertise.
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • Treatment Resistance
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Two experts offer a refresher on predictors and identification of treatment-resistant schizophrenia. Drs Correll and Howes also review therapeutic strategies.
  • Bipolar Disorder
  • Depression
  • Antipsychotics
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.

Pages